The Role of MUC1 in Gastric Cancer Development

TL;DR

This review discusses how MUC1, a glycoprotein, contributes to gastric cancer development and its potential as a biomarker for early diagnosis and treatment.

Contribution

The paper provides a comprehensive review of MUC1's role in gastric cancer progression and its potential as a diagnostic biomarker.

Findings

MUC1 is overexpressed and aberrantly glycosylated in gastric cancer.

Altered MUC1 glycosylation contributes to a cancerous environment.

MUC1 is proposed as a potential biomarker for predicting gastric cancer outcomes.

Abstract

Gastric cancer (GC) is among the leading causes of death worldwide, mainly due to late diagnoses. Thus, an important challenge is identifying sensitive and accurate biomarkers that enable the early diagnosis and treatment of this cancer. One such candidate is MUC1, a transmembrane glycoprotein, which is overexpressed and specifically glycosylated in many cancers. The present review summarizes the role of MUC1 in gastric cancer development.

Gastric cancer (GC) remains the most common malignancy and the main cause of cancer-related death worldwide. Due to its asymptomatic beginning, most gastric cancer cases are diagnosed in the advanced stages, which is connected with poor outcomes. Therefore, there is an urgent need for the development of early preventive and screening strategies for GC. A full understanding of GC pathogenesis, including examining key factors participating in cancer progress, is important. MUC1 is a glycoprotein that is highly overexpressed in most epithelial tumors, including gastric tumors. MUC1 presents a specifically altered glycosylation pattern, which is important for the creation of a cancerous environment. This mucin has been proposed as a biomarker for predicting GC outcomes. This review summarizes the involvement of MUC1 in GC progression.

Figures